Comparative Pharmacology
Head-to-head clinical analysis: BUTENAFINE HYDROCHLORIDE versus EXTINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTENAFINE HYDROCHLORIDE versus EXTINA.
BUTENAFINE HYDROCHLORIDE vs EXTINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits squalene epoxidase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Antifungal agent that inhibits the enzyme 14α-demethylase, blocking the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.
1% cream applied topically once daily for 2 weeks for tinea pedis, 1 week for tinea corporis/cruris.
2.5% to 3.5% solution applied topically twice daily for 4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 35–40 hours following topical application; long half-life supports once-daily dosing.
Terminal elimination half-life is approximately 24-32 hours in adults, allowing once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Primarily metabolized in the liver; minimal excretion of unchanged drug. Less than 5% of a topical dose is absorbed systemically; excreted in urine and feces as metabolites.
Primarily renal excretion of unchanged drug (approximately 80-90% of the absorbed dose), with minor hepatic metabolism and fecal elimination (<10%).
Category C
Category C
Antifungal
Antifungal